CSPC PHARMACEUT.GR. ADR4 Cash Flow-to-Debt Ratio
CSPC PHARMACEUT.GR. ADR4 cash flow-to-debt ratio. CSPC PHARMACEUT.GR. ADR4 (CVGU) has a Cash Flow-to-Debt Ratio of 0.48x as of December 2025, meaning its operating cash flow of €5.83 Billion could theoretically repay 0% of its total liabilities (€12.15 Billion) in one year. Check cash flow quality index of CSPC PHARMACEUT.GR. ADR4 to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Cash flow-to-debt ratio of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. Historical debt coverage capacity for CSPC PHARMACEUT.GR. ADR4 across 5 annual periods. Check CSPC PHARMACEUT.GR. ADR4 (CVGU) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CSPC PHARMACEUT.GR. ADR4 Cash Flow-to-Debt Ratio by Year (2021–2025)
CSPC PHARMACEUT.GR. ADR4 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for CSPC PHARMACEUT.GR. ADR4. For the full cash flow conversion analysis, see CSPC PHARMACEUT.GR. ADR4 (CVGU) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | €5.83 Billion | €12.15 Billion | ▲ +11.4% |
| 2024 | 0.43x | €4.53 Billion | €10.52 Billion | ▲ +16.2% |
| 2023 | 0.37x | €4.18 Billion | €11.26 Billion | ▼ -50.7% |
| 2022 | 0.75x | €7.63 Billion | €10.13 Billion | ▲ +28.5% |
| 2021 | 0.59x | €4.64 Billion | €7.91 Billion | — |